Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Leukemia, Myelomonocytic, Chronic 2Leukemia 2Anemia, Refractory, with Excess of Blasts 2Anemia 2beta-Thalassemia 1Thrombocytopenia 1Thalassemia 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neutropenia 1Myelodysplastic Syndromes 1Multiple Myeloma 1Fatigue 1Anemia, Sickle Cell 1Anemia, Refractory 1

Interventions

fludarabine phosphate 4fludarabine 4Cyclophosphamide 4Thiotepa 3Melphalan 3Whole-Body Irradiation 2Tacrolimus 2Surveys and Questionnaires 2Fentanyl 2Busulfan 2Alemtuzumab 2AP 1903 reagent 2voxelotor 1thymoglobulin 1maltodextrin 1Rituximab 1Registries 1Range of Motion, Articular 1Protease Inhibitors 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Medical Marijuana 1Interviews as Topic 1Imagery, Psychotherapy 1Holistic Health 1Glutamine 1Erythrocyte Count 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia, Sickle Cell × Dexamethasone × Classical hematology × Clear all
NCT05736419 2026-06-03

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡